Generation Bio (GBIO) to Release Quarterly Earnings on Wednesday

Generation Bio (NASDAQ:GBIO) is anticipated to issue its quarterly earnings data before the market opens on Wednesday, March 5th. Analysts expect the company to announce earnings of ($0.31) per share and revenue of $2.92 million for the quarter.

Generation Bio Stock Down 7.4 %

Generation Bio stock opened at $0.54 on Tuesday. The company has a fifty day simple moving average of $0.84 and a 200-day simple moving average of $1.65. The firm has a market capitalization of $35.87 million, a price-to-earnings ratio of -0.25 and a beta of 2.69. Generation Bio has a 52-week low of $0.53 and a 52-week high of $4.65.

Insider Buying and Selling

In other Generation Bio news, Director Anthony G. Quinn purchased 85,000 shares of the firm’s stock in a transaction that occurred on Monday, January 13th. The stock was purchased at an average price of $0.97 per share, for a total transaction of $82,450.00. Following the purchase, the director now directly owns 299,286 shares in the company, valued at approximately $290,307.42. This trade represents a 39.67 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 21.10% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the stock. Needham & Company LLC decreased their target price on shares of Generation Bio from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, January 8th. Wedbush reaffirmed an “outperform” rating and issued a $5.00 target price on shares of Generation Bio in a research report on Thursday, November 7th.

About Generation Bio

Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.